CD274 and cancer: Immune checkpoint inhibitors, which boost the immune response against cancer cells by targeting either programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1), are establishing themselves in triple-negative disease, becoming the first line of therapy in association with chemotherapy in case PD-L1 positive disease (50, 51).